Amneal Pharmaceuticals, Inc. (AMRX)

Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Amneal Pharmaceuticals, Inc. (AMRX)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NYSE: AMRX). The investigation concerns whether Amneal and certain of its officers and/or directors have violated federal securities laws.


On July 10, 2019, Amneal cut its 2019 core earnings forecast, citing the uncertain supply of epinephrine auto-injectors amid a global shortage of the emergency allergy shots, including Mylan NV’s EpiPen.  Amneal also cited delays in regulatory approvals and launches as other reasons for the lowered forecast.  On this news, Amneal’s stock price fell $2.45 per share, or 35.98%, to close at $4.36 per share on July 10, 2019.

If you are aware of any facts relating to this investigation, or purchased Amneal shares, you can learn more about the investigation by contacting Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484


Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

© 2019 Bronstein, Gewirtz & Grossman, LLC

  • Twitter Social Icon

BG&G is not affiliated to any of these companies. All respective trademarks are owned by the respective companies.